FBB Biomed joins its first clinical trial
FBB Biomed joins clinical trial in partnership with MaxWell Clinic to measure the impact of therapeutic plasma exchange on FBB’s proprietary biomarkers in Alzheimer’s Disease patients
Click here to read the announcement by FBB’s CEO
FBB Biomed’s reagent enables novel next-generation sequencing (NGS) diagnostics. A FBB test provides neurologists with a liquid biopsy for brain diseases.
Our test runs on standard laboratory sequencing equipment and protocols. No new hardware or processes required.
"Which specific neurologic disease does this patient have?"
"How effective has the therapy been for this specific patient?"
© 2023 All Rights Reserved